secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001104659-22-085182
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ReShape Lifesciences appoints Paul F. Hickey as CEO, effective Aug 15, 2022
---------------------------------------------------------------------------

- Paul F. Hickey appointed President and CEO, succeeds Bart Bandy who departed to pursue other opportunities.
- CFO Thomas Stankovich serves as interim CEO until Hickey joins; Dan Gladney becomes Executive Chair.
- Hickey receives $400K base salary, bonus up to 50% of salary, and stock option grant of 4% fully diluted shares.
- Stankovich receives retention bonus of 100% target 2022 cash bonus if employed through Dec 31, 2022.
- Hickey previously SVP Marketing at EnteroMedics (predecessor ReShape) and CEO at Altimate Medical.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000110465922085182/0001104659-22-085182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000110465922085182/tm2222383d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-085182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer